- Home
- LLYVA vs LEGN Comparison
LLYVA vs LEGN Comparison
Compare LLYVA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLYVA | LEGN |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LLYVA | LEGN |
|---|---|---|
| Price | $90.30 | $18.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $63.08 |
| AVG Volume (30 Days) | 144.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.27 |
| Revenue Next Year | $9.89 | $28.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.70 | $16.24 |
| 52 Week High | $99.63 | $45.30 |
Technical Indicators
Market Signals| Indicator | LLYVA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 49.02 |
| Support Level | $78.00 | $17.46 |
| Resistance Level | $91.50 | $23.68 |
| Average True Range (ATR) | 3.49 | 0.81 |
| MACD | -0.82 | 0.16 |
| Stochastic Oscillator | 2.98 | 47.10 |
Price Performance
Historical ComparisonAbout LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Holdings Inc focuses on live entertainment investments. The company maintains a substantial ownership position in Live Nation Entertainment, the primary international promoter of concerts, events, and ticketing through platforms like Ticketmaster, alongside sponsorship and hospitality services via QuintEvents.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.